A detailed history of Goldman Sachs Group Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,067,460 shares of NTLA stock, worth $22.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,067,460
Previous 824,527 29.46%
Holding current value
$22.8 Million
Previous $25.1 Million 16.81%
% of portfolio
0.01%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$23.82 - $32.8 $5.79 Million - $7.97 Million
242,933 Added 29.46%
1,067,460 $29.4 Million
Q4 2023

Feb 13, 2024

BUY
$23.16 - $32.34 $654,594 - $914,057
28,264 Added 3.55%
824,527 $25.1 Million
Q3 2023

May 14, 2024

SELL
$31.62 - $45.78 $893,707 - $1.29 Million
-28,264 Reduced 3.43%
796,263 $25.2 Million
Q3 2023

Nov 14, 2023

SELL
$31.62 - $45.78 $6.56 Million - $9.5 Million
-207,503 Reduced 20.67%
796,263 $25.2 Million
Q2 2023

May 14, 2024

BUY
$34.58 - $46.03 $4.99 Million - $6.64 Million
144,284 Added 16.79%
1,003,766 $40.9 Million
Q2 2023

Aug 14, 2023

BUY
$34.58 - $46.03 $4.99 Million - $6.64 Million
144,284 Added 16.79%
1,003,766 $40.9 Million
Q1 2023

May 14, 2024

BUY
$33.3 - $44.82 $7.74 Million - $10.4 Million
232,388 Added 37.06%
859,482 $32 Million
Q1 2023

May 11, 2023

BUY
$33.3 - $44.82 $7.74 Million - $10.4 Million
232,388 Added 37.06%
859,482 $32 Million
Q4 2022

May 14, 2024

SELL
$33.21 - $62.69 $11.8 Million - $22.2 Million
-354,661 Reduced 36.13%
627,094 $21.9 Million
Q4 2022

Feb 13, 2023

SELL
$33.21 - $62.69 $11.8 Million - $22.2 Million
-354,661 Reduced 36.13%
627,094 $21.9 Million
Q3 2022

May 14, 2024

BUY
$53.92 - $71.7 $7.2 Million - $9.58 Million
133,572 Added 15.75%
981,755 $54.9 Million
Q3 2022

Nov 10, 2022

BUY
$53.92 - $71.7 $7.2 Million - $9.58 Million
133,572 Added 15.75%
981,755 $54.9 Million
Q2 2022

May 14, 2024

BUY
$38.49 - $76.21 $910,519 - $1.8 Million
23,656 Added 2.87%
848,183 $43.9 Million
Q2 2022

Aug 15, 2022

BUY
$38.49 - $76.21 $12.2 Million - $24.2 Million
317,167 Added 59.73%
848,183 $43.9 Million
Q1 2022

May 16, 2022

SELL
$58.27 - $118.99 $26.8 Million - $54.7 Million
-460,075 Reduced 46.42%
531,016 $38.6 Million
Q4 2021

Feb 14, 2022

BUY
$100.76 - $138.36 $2.1 Million - $2.88 Million
20,801 Added 2.14%
991,091 $117 Million
Q3 2021

Nov 10, 2021

BUY
$132.37 - $176.78 $128 Million - $172 Million
970,290 New
970,290 $130 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.63B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.